Eisai Co., Ltd.'s (ESAIY) supplemental Biologics License Application for Leqembi iqlik, as a subcutaneous weekly starting dose, for the treatment of early Alzheimer's disease, is under priority review by the FDA, with a decision expected on May 24, 2026.Leqembi Iqlik subcutaneous injection was approved in the U.S. for maintenance dosing for the treatment of early Alzheimer's disease last August.Leqembi iqlik autoinjectors contain the same active medicine (lecanemab) as Leqembi, which is administered as an intravenous (IV) infusion.Eisai leads the global development and regulatory filings for lecanemab. Eisai and Biogen (BIIB) jointly commercialize and promote the product, with Eisai retaining final decision-making authority.ESAIY closed Monday's trading at $7.09, down 3.67%.